CELLSEEKER
DEAD

Serial Number

98795718

Owner

CAPSTAN THERAPEUTICS, INC.

Attorney

Joi A. White

Filing Date

Oct 10, 2024

Add to watchlist:

No watchlists yet
View on USPTO

CELLSEEKER Trademark

Serial Number: 98795718

CELLSEEKER is a trademark filed by CAPSTAN THERAPEUTICS, INC. on October 10, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CAPSTAN THERAPEUTICS, INC. (4 trademarks)

9880 Campus Point Drive, Suite 220
San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

October 10, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; systems to express therapeutic proteins in vivo; gene therapy products; gene therapy preparations; in vivo nucleic acid, DNA, RNA, and mRNA technologies; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; cell engineering platforms; cell engineering platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy; technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; technology platforms for delivery of a nucleic acid payload; technology platforms for delivery of a negatively charged payload; biologics delivery systems; biologics delivery platforms; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles;

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 16, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 16, 2025 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 30, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 30, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 3, 2025 GNRN
NON-FINAL ACTION E-MAILED
Apr 3, 2025 GNRT
NON-FINAL ACTION WRITTEN
Apr 3, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 21, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 11, 2024 NWOS
NEW APPLICATION ENTERED
Oct 11, 2024 NWAP